{"Study":{"7":"EA8185","8":"NRG-LU007","11":"NRG-CC008","13":"NRG-GI007","14":"S1914","15":"S1806","16":"NRG-GU008","17":"NRG-GY020","18":"NRG-LU006","21":"NRG-GY022","22":"NRG-GY019","24":"NRG-GY018","28":"GOG-0238","30":"NRG-GU007","31":"RTOG-1112","32":"NRG-HN005","33":"NRG-LU003","35":"NRG-DT001","37":"NRG-LU005","38":"NRG-LU002","54":"NRG-LU004","56":"NRG-CC007CD","57":"NRG-HN004","59":"NRG-BR004","61":"NRG-GI006","65":"NRG-GY006","70":"NRG-GU005","73":"NRG-HN001","74":"GOG-0278","77":"RTOG-1308","78":"NRG-GI003","79":"NRG-BN003","80":"NRG-BN005","85":"AGCT1531","142":"GOG-0263","144":"NRG-GI004\/SWOG-S1610","158":"NRG-BR003","162":"RTOG-1008","164":"RTOG-0724","166":"RTOG-1216","181":"SWOG-S1207 NSABP B-53","182":"SWOG-S1418 NRG-BR006","186":"NRG-BN001","188":"NRG-GU002"},"Title":{"7":"ECOG-ACRIN\/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study","8":"RAndomized Phase II\/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial","11":"A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]","13":"Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for Surgery","14":"SWOG\/NRG Joint Study: A Randomized Phase III Trial of Induction\/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC","15":"SWOG\/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer","16":"Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy","17":"A Phase III Randomized Trial of Radiation +\/- Pembrolizumab (MK-3475) for Newly Diagnosed, Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer","18":"Phase III Randomized Trial of Pleurectomy\/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)","21":"Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin","22":"A Randomized Phase III, Two-Arm Trial of Paclitaxel\/Carboplatin\/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum","24":"A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER","28":"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus","30":"Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)","31":"Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma","32":"A Randomized Phase II\/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer","33":"A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol","35":"A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)","37":"Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II\/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab","38":"Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II\/III Trial","54":"Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)","56":"Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy","57":"Randomized Phase II\/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin","59":"A Randomized, Double-Blind, Phase III Trial of Paclitaxel\/Trastuzumab\/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer","61":"Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer","65":"A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer","70":"Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer","73":"Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)","74":"Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (&lt;\/= 2 cm) Cervical Cancer","77":"Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC","78":"A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma","79":"Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma","80":"A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.","85":"A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors","142":"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I\/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphdenectomy.","144":"Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6\/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer","158":"A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer","162":"A Randomized Phase II\/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors","164":"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy","166":"Randomized Phase II\/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck","181":"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +\/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2\/neu Negative Breast Cancer: e3 Breast Cancer Study - Evaluating Everolimus with Endocrine Therapy","182":"A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy","186":"Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma","188":"NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel"},"Status":{"7":"Open to Accrual","8":"Open to Accrual","11":"Open to Accrual","13":"Open to Accrual","14":"Open to Accrual","15":"Open to Accrual","16":"Open to Accrual","17":"Open to Accrual","18":"Open to Accrual","21":"Open to Accrual","22":"Open to Accrual","24":"Open to Accrual","28":"Open to Accrual","30":"Open to Accrual","31":"Open to Accrual","32":"Open to Accrual","33":"Open to Accrual","35":"Open to Accrual","37":"Open to Accrual","38":"Open to Accrual","54":"Open to Accrual","56":"Open to Accrual","57":"Open to Accrual","59":"Open to Accrual","61":"Open to Accrual","65":"Open to Accrual","70":"Open to Accrual","73":"Open to Accrual","74":"Open to Accrual","77":"Open to Accrual","78":"Open to Accrual","79":"Open to Accrual","80":"Open to Accrual","85":"Open to Accrual","142":"Open to Accrual","144":"Open to Accrual","158":"Open to Accrual","162":"Open to Accrual","164":"Open to Accrual","166":"Open to Accrual","181":"Open to Accrual","182":"Open to Accrual","186":"Open to Accrual","188":"Open to Accrual"},"Phase":{"7":"II","8":"II\/III","11":"Other","13":"I","14":"III","15":"III","16":"III","17":"III","18":"III","21":"II","22":"III","24":"III","28":"II","30":"I\/II","31":"III","32":"II\/III","33":"II","35":"I","37":"II\/III","38":"II\/III","54":"I","56":"II","57":"II\/III","59":"III","61":"III","65":"II","70":"III","73":"II\/III","74":"I\/II","77":"III","78":"III","79":"III","80":"II","85":"III","142":"III","144":"III","158":"III","162":"II\/III","164":"III","166":"II\/III","181":"III","182":"III","186":"II","188":"II\/III"},"Disease Category":{"7":"Genitourinary [GU]","8":"Lung [LU]","11":"Gynecologic [GY]","13":"Gastrointestinal [GI]","14":"Lung [LU]","15":"Genitourinary [GU]","16":"Genitourinary [GU]","17":"Gynecologic [GY]","18":"Lung [LU]","21":"Gynecologic [GY]","22":"Gynecologic [GY]","24":"Gynecologic [GY]","28":"Gynecologic [GY]","30":"Genitourinary [GU]","31":"Gastrointestinal [GI]","32":"Head and Neck [HN]","33":"Lung [LU]","35":"Other [DT]","37":"Lung [LU]","38":"Lung [LU]","54":"Lung [LU]","56":"Symptom Management [CC]","57":"Head and Neck [HN]","59":"Breast [BR]","61":"Gastrointestinal [GI]","65":"Gynecologic [GY]","70":"Genitourinary [GU]","73":"Head and Neck [HN]","74":"Gynecologic [GY]","77":"Lung [LU]","78":"Gastrointestinal [GI]","79":"Brain [BN]","80":"Brain [BN]","85":"Gynecologic [GY]","142":"Gynecologic [GY]","144":"Gastrointestinal [GI]","158":"Breast [BR]","162":"Head and Neck [HN]","164":"Gynecologic [GY]","166":"Head and Neck [HN]","181":"Breast [BR]","182":"Breast [BR]","186":"Brain [BN]","188":"Genitourinary [GU]"},"Disease Site":{"7":"Bladder","8":"Small Cell","11":"Ovarian","13":"Esophageal","14":"Other","15":"Bladder","16":"Prostate","17":"Uterine Corpus","18":"Other","21":"Other","22":"Ovarian","24":"Uterine Corpus","28":"Uterine Corpus","30":"Prostate","31":"Liver","32":"Head and Neck","33":"Other","35":"Sarcoma","37":"Small Cell","38":"Other","54":"Other","56":"Other","57":"Head and Neck","59":"Breast","61":"Esophageal","65":"Cervix","70":"Prostate","73":"Head and Neck","74":"Cervix","77":"Other","78":"Liver","79":"Benign Brain Tumors","80":"Lower Grade Glioma","85":"Other","142":"Cervix","144":"Colorectal","158":"Breast","162":"Head and Neck","164":"Ovarian","166":"Head and Neck","181":"Breast","182":"Breast","186":"Malignant Glioma","188":"Prostate"},"Enrolled":{"7":"","8":"","11":"","13":"","14":"","15":"","16":"","17":"","18":"","21":"","22":"","24":"","28":"","30":"","31":"","32":"","33":"","35":"","37":"","38":"","54":"","56":"","57":"","59":"","61":"","65":"","70":"","73":"","74":"","77":"","78":"","79":"","80":"","85":"","142":"","144":"","158":"","162":"","164":"","166":"","181":"","182":"","186":"","188":""},"Planned":{"7":"","8":"","11":"","13":"","14":"","15":"","16":"","17":"","18":"","21":"","22":"","24":"","28":"","30":"","31":"","32":"","33":"","35":"","37":"","38":"","54":"","56":"","57":"","59":"","61":"","65":"","70":"","73":"","74":"","77":"","78":"","79":"","80":"","85":"","142":"","144":"","158":"","162":"","164":"","166":"","181":"","182":"","186":"","188":""}}